Results 241 to 250 of about 1,594,004 (375)
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
The body fluids: Basic physiology and practical therapeutics [PDF]
Louis M. Hellman
openalex +1 more source
Pediatric Applications of Digital Therapeutics: Clinical Evidence and Implementation Landscape. [PDF]
Chamarthi VS.
europepmc +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
CONSIDERATIONS ON THE PATHOLOY AND THERAPEUTICS OF EPILEPSY [PDF]
J. Leonard Corning
openalex +1 more source
Decrypting cancer's spatial code: from single cells to tissue niches
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik +4 more
wiley +1 more source
A sweet barrier to gene silencing: Glucose metabolism interferes with antisense oligonucleotide therapy. [PDF]
Duan S, Zhang W, Cao H.
europepmc +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source

